MARKET

BFRI

BFRI

Biofrontera Inc
NASDAQ
0.6497
-0.0502
-7.18%
After Hours: 0.6300 -0.0197 -3.03% 19:57 05/16 EDT
OPEN
0.7100
PREV CLOSE
0.6999
HIGH
0.7100
LOW
0.6230
VOLUME
729.64K
TURNOVER
--
52 WEEK HIGH
2.220
52 WEEK LOW
0.6230
MARKET CAP
6.14M
P/E (TTM)
-0.2018
1D
5D
1M
3M
1Y
5Y
1D
Biofrontera, Inc. Reports Q1 2025 Financial Results
TipRanks · 2d ago
Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls
Seeking Alpha · 2d ago
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Biofrontera GAAP EPS of -$0.47 misses by $0.26, revenue of $8.6M misses by $1.95M
Seeking Alpha · 2d ago
Biofrontera Inc. reports Q1 EPS (47c) vs. ($2.88) last year
TipRanks · 3d ago
Biofrontera Inc. reports Q1 EPS (47c) vs. (71c) last year
TipRanks · 3d ago
BIOFRONTERA Q1 NET INCOME USD -4.2 MILLION
Reuters · 3d ago
*Biofrontera 1Q Loss/Shr 47c >BFRI
Dow Jones · 3d ago
More
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and is used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Webull offers Biofrontera Inc stock information, including NASDAQ: BFRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BFRI stock methods without spending real money on the virtual paper trading platform.